Progenics' (PGNX) Relistor Setback Only a Speedbump - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Needham & Company Defends Progenics (PGNX) on PDUFA Delay, Valeant Overhang
April 4, 2016 1:23 PM EDTNeedham & Company analyst Chad Messer has come out to defend Progenics Pharmaceuticals (NASDAQ: PGNX), which is down 6.5% after the FDA extended oral Relistor PDFUA by 3 months to July 19th. The FDA made the extension in order to review responses by Valeant to recent... More
Valeant Pharma (VRX), Progenics (PGNX) PDUFA for Oral RELISTOR Extended by 3 Months
April 4, 2016 7:03 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the Oral... More
